Latest Period
Q2 2026
Security Snapshot
MoonLake Immunotherapeutics - COMMON STOCK (MLTX) Institutional Ownership
CUSIP: 61559X104
13F Institutional Holders and Ownership History from Q1 2022 to Q2 2026
Institutions Reporting
171
Shares (Excl. Options)
73,175,874
Price
$19.47
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- MLTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 73,175,874
- Total 13F value
- $1,425,319,639
- Portfolio coverage rank
- 0%
- Share change
- +10,420,468
- Value change
- +$204,578,382
- Number of holders
- 171
- Shares outstanding
- 80,766,491
- SEC-reported price per share
- $19.68
- Insider filing price
- $19.68
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MLTX - MoonLake Immunotherapeutics - COMMON STOCK is tracked under CUSIP 61559X104.
- 171 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 147 to 171 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,173,300,860 to $1,425,319,639.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 171 institutions filings for Q2 2026.
Security key
61559X104
Latest holder period
Q2 2026
13F holders
171
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
MLTX full holder history
MoonLake Immunotherapeutics SEC filings
MoonLake Immunotherapeutics company facts
MoonLake Immunotherapeutics insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61559X104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
MLTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 20% | -12% | $298,903,985 | 16,001,284 | 0% | BVF PARTNERS L P/IL | 25 Jun 2026 | |
| Deep Track Capital, LP | 9.7% | +55% | $162,860,149 | +$68,999,103 | 7,999,025 | +74% | Deep Track Capital, LP | 30 Jun 2026 |
| T. Rowe Price Investment Management, Inc. | 5.3% | $87,153,505 | 4,280,624 | T. Rowe Price Investment Management, Inc. | 30 Jun 2026 | |||
| Cormorant Asset Management, LP | 4.4% | -32% | $65,262,616 | -$25,959,000 | 3,205,433 | -28% | Cormorant Asset Management, LP | 30 Jun 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.7% | -12% | $117,334,991 | -$14,571,725 | 2,974,271 | -11% | T. Rowe Price Associates, Inc. | 31 Mar 2025 |
| Avoro Capital Advisors LLC | 3.2% | -48% | $14,340,000 | -$15,415,500 | 2,000,000 | -52% | Avoro Capital Advisors LLC | 30 Sep 2025 |
| Chen Bihua | 3.1% | $108,084,177 | 1,994,173 | Chen Bihua | 30 Sep 2025 | |||
| FMR LLC | 1.1% | -88% | $5,212,098 | -$35,678,759 | 726,931 | -87% | FMR LLC | 30 Sep 2025 |
As of 30 Jun 2026, 171 institutional investors reported holding 73,175,874 shares of MoonLake Immunotherapeutics - COMMON STOCK (MLTX). This represents 91% of the company’s total 80,766,491 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
75%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 20% | 16,001,284 | 0% | 8% | $311,544,999 |
| Deep Track Capital, LP | 8.7% | 6,999,025 | +9.2% | 2% | $136,271,017 |
| T. Rowe Price Investment Management, Inc. | 5.3% | 4,280,624 | 0.05% | $83,344,000 | |
| D. E. Shaw & Co., Inc. | 4.2% | 3,365,507 | +41% | 0.04% | $65,526,421 |
| Cormorant Asset Management, LP | 4% | 3,205,433 | -28% | 3.2% | $62,409,781 |
| Jupiter Topco LLC | 3.8% | 3,085,906 | 0% | 0.02% | $60,082,590 |
| Logos Global Management LP | 3.3% | 2,675,000 | +78% | 2.2% | $52,082,250 |
| Weiss Asset Management LP | 3.2% | 2,581,813 | +51% | 0.56% | $50,267,899 |
| CITADEL ADVISORS LLC | 2.4% | 1,972,893 | +49% | 0.02% | $38,412,227 |
| TWO SIGMA INVESTMENTS, LP | 2.1% | 1,715,349 | +53% | 0.03% | $33,397,845 |
| MPM BIOIMPACT LLC | 2% | 1,606,967 | -11% | 1.9% | $31,287,647 |
| Vivo Capital, LLC | 1.7% | 1,400,000 | +40% | 2.5% | $27,258,000 |
| JPMORGAN CHASE & CO | 1.7% | 1,386,422 | +27% | 0% | $27,603,662 |
| Point72 Asset Management, L.P. | 1.4% | 1,158,732 | -15% | 0.03% | $22,560,512 |
| BlackRock, Inc. | 1.4% | 1,094,791 | +7.1% | 0% | $21,315,581 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 1,041,527 | -20% | 0% | $20,279,000 |
| Balyasny Asset Management L.P. | 1.1% | 912,715 | -14% | 0.03% | $17,770,561 |
| GREAT POINT PARTNERS LLC | 1.1% | 855,813 | +71% | 3.9% | $16,662,679 |
| JANE STREET GROUP, LLC | 1.1% | 853,386 | +88% | 0.01% | $16,615,426 |
| Candriam S.C.A. | 0.95% | 769,766 | -5.9% | 0.07% | $14,972,924 |
| BANK OF AMERICA CORP /DE/ | 0.93% | 751,897 | +3.7% | 0% | $14,639,435 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.93% | 750,777 | +970% | 0.01% | $14,617,628 |
| Trails Edge Capital Partners, LP | 0.93% | 750,000 | 2.3% | $14,602,500 | |
| HRT FINANCIAL LP | 0.84% | 679,244 | +39% | 0.02% | $13,224,000 |
| RENAISSANCE TECHNOLOGIES LLC | 0.8% | 643,268 | +132% | 0.02% | $12,524,428 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q2 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 73,175,874 | $1,425,319,639 | +$204,578,382 | $19.47 | 171 |
| 2026 Q1 | 63,048,824 | $1,173,300,860 | +$130,740,817 | $18.64 | 147 |
| 2025 Q4 | 56,366,340 | $742,950,479 | +$285,748,230 | $13.18 | 131 |
| 2025 Q3 | 37,454,837 | $268,355,896 | -$543,765,841 | $7.17 | 132 |
| 2025 Q2 | 58,588,386 | $2,765,378,029 | -$36,637,296 | $47.20 | 129 |
| 2025 Q1 | 59,723,013 | $2,333,397,891 | -$153,122,113 | $39.07 | 134 |
| 2024 Q4 | 63,244,825 | $3,424,722,298 | +$68,390,992 | $54.15 | 114 |
| 2024 Q3 | 62,105,859 | $3,131,140,770 | +$81,133,174 | $50.42 | 108 |
| 2024 Q2 | 60,656,094 | $2,667,012,692 | +$45,095,266 | $43.97 | 109 |
| 2024 Q1 | 59,346,206 | $2,980,958,004 | +$1,466,170 | $50.23 | 112 |
| 2023 Q4 | 58,433,271 | $3,528,831,635 | +$147,969,282 | $60.39 | 124 |
| 2023 Q3 | 56,323,727 | $3,210,450,399 | +$46,563,145 | $57.00 | 118 |
| 2023 Q2 | 56,057,516 | $2,858,934,462 | +$861,230,424 | $51.00 | 82 |
| 2023 Q1 | 39,419,149 | $843,176,754 | +$59,244,738 | $21.39 | 43 |
| 2022 Q4 | 37,748,780 | $396,358,589 | +$8,234,061 | $10.50 | 32 |
| 2022 Q3 | 36,855,847 | $291,356,995 | +$3,123,162 | $7.76 | 24 |
| 2022 Q2 | 36,470,008 | $190,106,000 | +$182,848,000 | $5.25 | 22 |
| 2022 Q1 | 653,872 | $7,258,000 | +$7,258,000 | $11.10 | 1 |